Search research articles
Contact Us
Filters
Showing results (11-20 of 24) with videos related to
Page
of 3
Sort By:
Bioanalysis
|
May 19, 2017
Novel drug and soluble target tolerant antidrug antibody assay for therapeutic antibodies bearing the P329G mutation
Uwe Wessels, Eginhard Schick, Mirko Ritter, et al.
Bioanalysis
|
October 21, 2015
Quantification of a bifunctional drug in the presence of an immune response: a ligand-binding assay specific for 'active' drug
Roland F Staack, Gregor Jordan, Maria Viert, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 29, 2015
Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics
Angela Schoch, Hubert Kettenberger, Olaf Mundigl, et al.
Neuro-Signals
|
July 14, 2006
Cyclic-AMP response element-based signaling assays for characterization of Trk family tyrosine kinases modulators
Jie Zhang, Diana Chen, Xiaohai Gong, et al.
Journal of Pharmaceutical and Biomedical Analysis
|
December 3, 2014
An immunodepletion procedure advances free angiopoietin-2 determination in human plasma samples during anti-cancer therapy with bispecific anti-Ang2/VEGF CrossMab
Kay Stubenrauch, Uwe Wessels, Ulrich Essig, et al.
Bioanalysis
|
November 4, 2016
Validation of a ligand-binding assay for active protein drug quantification following the 'free analyte QC concept'
Eginhard Schick, Roland F Staack, Markus Haak, et al.
Bioanalysis
|
April 12, 2018
Immunogenicity testing of therapeutic antibodies in ocular fluids after intravitreal injection
Uwe Wessels, Markus Zadak, Astrid Reiser, et al.
Bioanalysis
|
September 2, 2016
Detection of antidrug antibodies against human therapeutic antibodies lacking Fc-effector functions by usage of soluble Fcγ receptor I
Uwe Wessels, Alexander Poehler, Miriam Moheysen-Zadeh, et al.
Bioanalysis
|
October 7, 2015
An ex vivo potency assay to assess active drug levels of a GLP-1 agonistic peptide during preclinical safety studies
Martin Schäfer, Steven Challand, Eginhard Schick, et al.
Journal of Immunological Methods
|
January 21, 2015
A fit-for-purpose strategy for the risk-based immunogenicity testing of biotherapeutics: a European industry perspective
Cathelijne Kloks, Claudia Berger, Pierre Cortez, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 24) with videos related to
Sort By:
Page
of 3
Bioanalysis
|
May 19, 2017
Novel drug and soluble target tolerant antidrug antibody assay for therapeutic antibodies bearing the P329G mutation
Uwe Wessels, Eginhard Schick, Mirko Ritter, et al.
Bioanalysis
|
October 21, 2015
Quantification of a bifunctional drug in the presence of an immune response: a ligand-binding assay specific for 'active' drug
Roland F Staack, Gregor Jordan, Maria Viert, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 29, 2015
Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics
Angela Schoch, Hubert Kettenberger, Olaf Mundigl, et al.
Neuro-Signals
|
July 14, 2006
Cyclic-AMP response element-based signaling assays for characterization of Trk family tyrosine kinases modulators
Jie Zhang, Diana Chen, Xiaohai Gong, et al.
Journal of Pharmaceutical and Biomedical Analysis
|
December 3, 2014
An immunodepletion procedure advances free angiopoietin-2 determination in human plasma samples during anti-cancer therapy with bispecific anti-Ang2/VEGF CrossMab
Kay Stubenrauch, Uwe Wessels, Ulrich Essig, et al.
Bioanalysis
|
November 4, 2016
Validation of a ligand-binding assay for active protein drug quantification following the 'free analyte QC concept'
Eginhard Schick, Roland F Staack, Markus Haak, et al.
Bioanalysis
|
April 12, 2018
Immunogenicity testing of therapeutic antibodies in ocular fluids after intravitreal injection
Uwe Wessels, Markus Zadak, Astrid Reiser, et al.
Bioanalysis
|
September 2, 2016
Detection of antidrug antibodies against human therapeutic antibodies lacking Fc-effector functions by usage of soluble Fcγ receptor I
Uwe Wessels, Alexander Poehler, Miriam Moheysen-Zadeh, et al.
Bioanalysis
|
October 7, 2015
An ex vivo potency assay to assess active drug levels of a GLP-1 agonistic peptide during preclinical safety studies
Martin Schäfer, Steven Challand, Eginhard Schick, et al.
Journal of Immunological Methods
|
January 21, 2015
A fit-for-purpose strategy for the risk-based immunogenicity testing of biotherapeutics: a European industry perspective
Cathelijne Kloks, Claudia Berger, Pierre Cortez, et al.
Page
of 3